Rosalind Advisors Inc. Makes New $10.61 Million Investment in Chimerix, Inc. (NASDAQ:CMRX)

Rosalind Advisors Inc. acquired a new stake in shares of Chimerix, Inc. (NASDAQ:CMRX - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 3,050,000 shares of the biopharmaceutical company's stock, valued at approximately $10,614,000. Chimerix makes up 5.3% of Rosalind Advisors Inc.'s investment portfolio, making the stock its 4th biggest holding. Rosalind Advisors Inc. owned 3.39% of Chimerix at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Peapod Lane Capital LLC bought a new position in shares of Chimerix during the fourth quarter valued at $2,626,000. Assenagon Asset Management S.A. lifted its stake in Chimerix by 154.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 817,739 shares of the biopharmaceutical company's stock valued at $2,846,000 after acquiring an additional 496,823 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Chimerix by 66.8% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after acquiring an additional 138,098 shares during the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Chimerix by 78.8% in the fourth quarter. Valeo Financial Advisors LLC now owns 146,186 shares of the biopharmaceutical company's stock worth $509,000 after acquiring an additional 64,420 shares during the period. Finally, Palumbo Wealth Management LLC purchased a new position in shares of Chimerix during the fourth quarter valued at approximately $221,000. 45.42% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on CMRX shares. StockNews.com began coverage on shares of Chimerix in a report on Sunday. They issued a "hold" rating on the stock. HC Wainwright restated a "neutral" rating and issued a $8.55 price target (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. Wedbush reiterated a "neutral" rating and set a $8.55 price objective (up previously from $7.00) on shares of Chimerix in a research report on Wednesday, March 5th. Finally, Jefferies Financial Group reissued a "hold" rating and issued a $8.50 target price (down from $10.00) on shares of Chimerix in a research report on Wednesday, March 5th.

Chimerix Stock Up 0.1 %

CMRX traded up $0.01 during trading on Wednesday, hitting $8.52. The company's stock had a trading volume of 1,225,906 shares, compared to its average volume of 2,100,241. The business's 50 day simple moving average is $5.55 and its 200-day simple moving average is $2.96. The firm has a market cap of $766.25 million, a PE ratio of -9.06 and a beta of 0.32. Chimerix, Inc. has a one year low of $0.75 and a one year high of $8.53.

Chimerix (NASDAQ:CMRX - Get Free Report) last announced its earnings results on Friday, March 21st. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.01. The company had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.31 million. Equities research analysts expect that Chimerix, Inc. will post -0.99 EPS for the current fiscal year.

Insider Activity

In related news, CEO Michael T. Andriole sold 7,370 shares of the business's stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total value of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares of the company's stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold 20,760 shares of company stock worth $91,175 in the last three months. Company insiders own 13.10% of the company's stock.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.